Hormonal Effects of a 5α-Reductase Inhibitor (Finasteride) on Hormonal Levels in Normal Men and in Patients with Benign Prostatic Hyperplasia
| Autor: | Vito Angelo Giagulli, Agnes Buntinx, Alex Vermeulen, P. De Schepper |
|---|---|
| Rok vydání: | 1991 |
| Předmět: |
Male
medicine.medical_specialty medicine.drug_class Urology Prostatic Hyperplasia 5 Alpha-Reductase Inhibitor chemistry.chemical_compound 5-alpha Reductase Inhibitors Internal medicine Humans Medicine Testosterone Dose-Response Relationship Drug Estradiol business.industry Finasteride Luteinizing Hormone Hyperplasia medicine.disease Androgen Endocrinology chemistry Azasteroids Toxicity Androgens Drug Evaluation Androstenes business Luteinizing hormone Hormone |
| Zdroj: | European Urology. 20:82-86 |
| ISSN: | 1873-7560 0302-2838 |
| DOI: | 10.1159/000471752 |
| Popis: | Finasteride is a potent competitive 5 alpha-reductase inhibitor, active at a dose as low as 1 mg/day. After a single dose, the effects on 5 alpha-reductase last as long as 7 days. Both hepatic and target tissue 5 alpha-reductase are inhibited. Plasma testosterone and estradiol are unaffected and luteinizing hormone levels do not change. During chronic treatment with finasteride 5 mg/day, the effects on 5 alpha-reductase are maintained. Since the only significant effect of chronic finasteride therapy appears to be 5 alpha-reductase inhibition, and testosterone or estradiol levels are not affected, neither libido nor potency is lost. Testosterone is the active androgen at the muscular level; therefore, muscular catabolism is not expected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|